iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
1. iBio reports transformative fiscal year 2025 with progress on key therapies. 2. IBIO-610 shows potential for weight loss with muscle preservation in preclinical studies. 3. Successful Nasdaq listing enhances visibility and supports capital raising efforts. 4. Corporate leadership strengthened with experienced biotech veterans on the Board. 5. Revenue increased to $0.4 million, but operational losses remain a concern.